Infinity Pharma Posts 52% Increase In One-Year Progression Free Survival Rate In Breast Cancer Patients

Infinity Pharmaceuticals Inc INFI reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple-negative breast cancer (TNBC) patients.
Sixty-two patients were enrolled and evaluable for safety, and 57 (were evaluable for efficacy, with a median duration of follow-up of 10.0 months.
Encouraging one-year progression-free survival rates in MARIO-3 1L TNBC study regardless of PD-L1 status.
52% increase in one-year progression-free survival rate in ITT patient population compared to the IMpassion130 benchmark.
No new safety signals were observed during the extended period of treatment, and the MARIO-3 safety profile continued to be consistent with expectations for the three component drugs.
74% of patients were able to remain on treatment with the MARIO-3 TNBC triplet regimen compared to 81% of patients with the IMpassion130 doublet.
Cash runway into 2024 with $47.2 million in cash & cash equivalents at the end of Q3 2022.
Infinity expects net loss for 2022 to range from $40 million to $50 million.
Price Action: INFI shares are down 24.20% at $0.90 on the last check Monday.